Cargando…
Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting
BACKGROUND: This phase IV routine care study evaluated ovarian responses when using a biosimilar follitropin alfa r-hFSH (Bemfola(®)) for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART) treatment who were pituitary-suppressed with a gonadotrophin-relea...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Avicenna Research Institute
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143010/ https://www.ncbi.nlm.nih.gov/pubmed/34041008 http://dx.doi.org/10.18502/jri.v22i2.5798 |
_version_ | 1783696667774550016 |
---|---|
author | Griesinger, Georg Schill, Thilo Sator, Michael Schenk, Michael Krüssel, Jan-Steffen |
author_facet | Griesinger, Georg Schill, Thilo Sator, Michael Schenk, Michael Krüssel, Jan-Steffen |
author_sort | Griesinger, Georg |
collection | PubMed |
description | BACKGROUND: This phase IV routine care study evaluated ovarian responses when using a biosimilar follitropin alfa r-hFSH (Bemfola(®)) for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART) treatment who were pituitary-suppressed with a gonadotrophin-releasing hormone (GnRH) antagonist. METHODS: This multicenter, prospective, non-comparative, non-interventional study (Germany/Austria) was conducted with 885 women (Mean age of 34.0±4.4 years) for whom COS with Bemfola(®) and GnRH-antagonist for pituitary suppression were applied as part of in vitro fertilization (IVF) treatment with/without intracytoplasmic sperm injection (ICSI) observing routine clinical-practice protocols. Primary endpoint was the number of retrieved cumulus-oocyte-complexes (COCs). RESULTS: Among 986 ART cycles, COS was given for 9.9±1.8 days (First-day r-hFSH dose of 220.7±68.9 IU; mean total dose of 2184.3±837.5 IU). It was revealed that 99.1% of cycles resulted in follicular puncture, with mean of 10.7±6.6 oocytes retrieved. Successful fertilization took place after IVF/ICSI in 93.8% of follicular punctures. Freeze-all was performed in 14.2% of cycles. Fresh embryo transfer was performed in 76.9% of cycles with follicular puncture; mean day of transfer was 3.5±1.3 and average number of transferred embryos was 1.76±0.50. Clinical pregnancy rate was 30.2% of embryo-transfer cycles and 23.4% of started cycles. Sixty-nine reports of ovarian hyperstimulation syndrome (7.0% of started cycles) were documented. CONCLUSION: COS with Bemfola(®) in GnRH-antagonist IVF/ICSI protocols in a routine care setting led to an appropriate ovarian response allowing oocyte retrieval in 99.1% of initiated cases. |
format | Online Article Text |
id | pubmed-8143010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Avicenna Research Institute |
record_format | MEDLINE/PubMed |
spelling | pubmed-81430102021-05-25 Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting Griesinger, Georg Schill, Thilo Sator, Michael Schenk, Michael Krüssel, Jan-Steffen J Reprod Infertil Original Article BACKGROUND: This phase IV routine care study evaluated ovarian responses when using a biosimilar follitropin alfa r-hFSH (Bemfola(®)) for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART) treatment who were pituitary-suppressed with a gonadotrophin-releasing hormone (GnRH) antagonist. METHODS: This multicenter, prospective, non-comparative, non-interventional study (Germany/Austria) was conducted with 885 women (Mean age of 34.0±4.4 years) for whom COS with Bemfola(®) and GnRH-antagonist for pituitary suppression were applied as part of in vitro fertilization (IVF) treatment with/without intracytoplasmic sperm injection (ICSI) observing routine clinical-practice protocols. Primary endpoint was the number of retrieved cumulus-oocyte-complexes (COCs). RESULTS: Among 986 ART cycles, COS was given for 9.9±1.8 days (First-day r-hFSH dose of 220.7±68.9 IU; mean total dose of 2184.3±837.5 IU). It was revealed that 99.1% of cycles resulted in follicular puncture, with mean of 10.7±6.6 oocytes retrieved. Successful fertilization took place after IVF/ICSI in 93.8% of follicular punctures. Freeze-all was performed in 14.2% of cycles. Fresh embryo transfer was performed in 76.9% of cycles with follicular puncture; mean day of transfer was 3.5±1.3 and average number of transferred embryos was 1.76±0.50. Clinical pregnancy rate was 30.2% of embryo-transfer cycles and 23.4% of started cycles. Sixty-nine reports of ovarian hyperstimulation syndrome (7.0% of started cycles) were documented. CONCLUSION: COS with Bemfola(®) in GnRH-antagonist IVF/ICSI protocols in a routine care setting led to an appropriate ovarian response allowing oocyte retrieval in 99.1% of initiated cases. Avicenna Research Institute 2021 /pmc/articles/PMC8143010/ /pubmed/34041008 http://dx.doi.org/10.18502/jri.v22i2.5798 Text en Copyright© 2021, Avicenna Research Institute. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Original Article Griesinger, Georg Schill, Thilo Sator, Michael Schenk, Michael Krüssel, Jan-Steffen Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting |
title | Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting |
title_full | Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting |
title_fullStr | Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting |
title_full_unstemmed | Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting |
title_short | Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting |
title_sort | clinical efficacy of follitropin alfa in gnrh-antagonist protocols: a prospective observational phase iv study on the use of biosimilar follitropin alfa r-hfsh in assisted reproductive technology in a routine care setting |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143010/ https://www.ncbi.nlm.nih.gov/pubmed/34041008 http://dx.doi.org/10.18502/jri.v22i2.5798 |
work_keys_str_mv | AT griesingergeorg clinicalefficacyoffollitropinalfaingnrhantagonistprotocolsaprospectiveobservationalphaseivstudyontheuseofbiosimilarfollitropinalfarhfshinassistedreproductivetechnologyinaroutinecaresetting AT schillthilo clinicalefficacyoffollitropinalfaingnrhantagonistprotocolsaprospectiveobservationalphaseivstudyontheuseofbiosimilarfollitropinalfarhfshinassistedreproductivetechnologyinaroutinecaresetting AT satormichael clinicalefficacyoffollitropinalfaingnrhantagonistprotocolsaprospectiveobservationalphaseivstudyontheuseofbiosimilarfollitropinalfarhfshinassistedreproductivetechnologyinaroutinecaresetting AT schenkmichael clinicalefficacyoffollitropinalfaingnrhantagonistprotocolsaprospectiveobservationalphaseivstudyontheuseofbiosimilarfollitropinalfarhfshinassistedreproductivetechnologyinaroutinecaresetting AT krusseljansteffen clinicalefficacyoffollitropinalfaingnrhantagonistprotocolsaprospectiveobservationalphaseivstudyontheuseofbiosimilarfollitropinalfarhfshinassistedreproductivetechnologyinaroutinecaresetting |